Issue Date: May 21, 2012
FDA User Fee Bills Move Swiftly
Congress is on track to pass legislation by the end of June that would reauthorize the Food & Drug Administration to collect fees from industry to help accelerate the review of new drugs and medical devices. Bills in both the House of Representatives and the Senate go beyond reauthorization of user fees and include several regulatory reform measures targeting drug safety and development, but lawmakers have refrained from adding controversial provisions in order to keep . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society